Core Insights - Arla Foods Ingredients has launched a new casein glycomacropeptide ingredient, Lacprodan®CGMP-30, which has a lower phenylalanine content, aiming to improve dietary adherence and overall quality of life for patients with phenylketonuria (PKU) [1][4][6] Group 1: Product Development - The new Lacprodan®CGMP-30 reduces phenylalanine content by approximately 50% compared to its predecessor, Lacprodan®CGMP-20, making it particularly suitable for patients who are more sensitive to phenylalanine [4][5] - Lacprodan®CGMP-20 has already shown health benefits, including improved gastrointestinal comfort and taste, when partially replacing free amino acid-based protein substitutes [4][5][6] Group 2: Market Need - PKU is a genetic metabolic disorder affecting approximately 1 in 24,000 newborns globally, with a higher incidence in China at about 1 in 16,000 [3][4] - Dietary management for PKU patients is challenging due to the need for lifelong low-protein diets and the poor palatability of traditional protein substitutes [3][4] Group 3: Safety and Applications - Both Lacprodan®CGMP-30 and Lacprodan®CGMP-20 are considered safe protein sources for PKU management and can be used in medical nutrition applications, including UHT beverages and powders [5][6] - The ingredients are also suitable for other rare congenital amino acid metabolic disorders, such as tyrosinemia and alkaptonuria, due to their low tyrosine content [5][6]